Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo,Asher Chanan-Khan,Katja Weisel,Ajay K. Nooka,Tamás Masszi,Meral Beksac,Ivan Spicka,Vania Hungria,Markus Munder,Maria-Victoria Mateos,Tomer M Mark,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tahamtan Ahmadi,Andrew Spencer,Pieter Sonneveld +18 more
Reads0
Chats0
TLDR
Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.Abstract:
BackgroundDaratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma. MethodsIn this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group). The primary end point was progression-free survival. ResultsA prespecified interim analysis showed that the rate of progression-free survival was significantly higher in the daratumumab group than in the control group; the 12-month rate of progression-free survival was 60.7% in the daratumumab group versus 26.9% in the control group. After a median follow-up period ...read more
Citations
More filters
Journal ArticleDOI
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Massimo Offidani,Laura Corvatta,Sara Bringhen,Silvia Gentili,Rossella Troia,Laura Maracci,Alessandra Larocca,Pietro Leoni,Mario Boccadoro +8 more
TL;DR: There is no strong evidence to guide therapeutic approach to multiple myeloma patients who experience first relapse, and the treatment choice can be difficult since currently all patients are exposed to novel agents as thalidomide, bortezomib and lenalidomides.
Journal ArticleDOI
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).
Faye Sharpley,Jemma Larham,Angus Haines,Faouzi Djebbari,Bing Tseu,Heather Leary,Grant Vallance,Fotios Panitsas,Lisa Ferguson,Pamela Roberts,Andrew Peniket,Sarah Gooding,Jaimal Kothari,Sally Moore,Karthik Ramasamy +14 more
TL;DR: The outcomes of 219 myeloma patients treated within the Thames Valley Cancer Alliance during the first wave of COVID-19, which was defined between the 1st of March and the 30th of June 2020, are described.
Journal ArticleDOI
Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma.
Anusha Bapatla,Arunima Kaul,Paramvijay Singh Dhalla,Ana S Armenta-Quiroga,Raheela Khalid,Jian Garcia,Safeera Khan +6 more
TL;DR: In this paper, the authors discuss the effect of the combination of daratumumab with the standard of care therapies in end-stage renal disease (ESRD) patients and show that the combination showed significant progression-free survival (PFS) without severe safety concerns.
Journal ArticleDOI
A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021
TL;DR: In this article , a research field study aimed to analyze all the relevant literature via bibliometrics to identify its course of development and structural relationships, and a total of 1,030 relevant articles were retrieved from the Web of Science Core Collection (WoSCC) from 1985 to June 21, 2021.
Journal ArticleDOI
Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
Congcong Cao,Xin Zhou,Qun Ma +2 more
TL;DR: Daratumumab was used in patients with relapsed or refractory multiple myeloma (MM) who previously received proteasome inhibitors or immunomodulatory drugs as discussed by the authors.
References
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
International uniform response criteria for multiple myeloma
Brian G.M. Durie,J L Harousseau,Jesús F. San Miguel,J. Bladé,Bart Barlogie,Kenneth C. Anderson,Morie A. Gertz,Meletios A. Dimopoulos,Johan Westin,Pieter Sonneveld,Heinz Ludwig,G. Gahrton,Meral Beksac,John Crowley,Andrew Belch,M. Boccadaro,Ingemar Turesson,Douglas E. Joshua,David H. Vesole,Robert A. Kyle,Raymond Alexanian,Guido Tricot,M. Attal,Giampaolo Merlini,R. L. Powles,Paul G. Richardson,K. Shimizu,Patrizia Tosi,Gareth J. Morgan,S V Rajkumar +29 more
TL;DR: The European Group for Blood and Bone Marrow Transplant/International Bone Marrows Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system to adequately assess clinical outcomes in myeloma.
Journal ArticleDOI
International staging system for multiple myeloma.
Philip R. Greipp,Jesús F. San Miguel,Brian G.M. Durie,John Crowley,Bart Barlogie,Joan Bladé,Mario Boccadoro,J. Anthony Child,Hervé Avet-Loiseau,Robert A. Kyle,Juan J. Lahuerta,Heinz Ludwig,Gareth J. Morgan,R. L. Powles,Kazuyuki Shimizu,Chaim Shustik,Pieter Sonneveld,Patrizia Tosi,Ingemar Turesson,Jan Westin +19 more
TL;DR: The new International Staging System (ISS) is simple, based on easy to use variables (Sbeta2M and serum albumin), and recommended for early adoption and widespread use.
Journal ArticleDOI
Discrete sequential boundaries for clinical trials
K. K. Gordon Lan,David L. DeMets +1 more
TL;DR: In this article, the authors proposed a more flexible method to construct discrete sequential boundaries based on the choice of a function, a*(t), which characterizes the rate at which the error level ac is spent.
Journal ArticleDOI
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Related Papers (5)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act,Sagar Lonial,Meletios A. Dimopoulos,Antonio Palumbo,Darrell White,Sebastian Grosicki,Ivan Spicka,Adam Walter‑Croneck,Philippe Moreau,Maria-Victoria Mateos,Hila Magen,Andrew Belch,Donna E. Reece,Meral Beksac,Andrew Spencer,Heather Oakervee,Robert Z. Orlowski,Masafumi Taniwaki,Christoph Röllig,Hermann Einsele,Ka Lung Wu,Anil K. Singhal,Jesús F. San Miguel,Morio Matsumoto,Jessica Katz,Eric Bleickardt,Valerie Poulart,Kenneth C. Anderson,Paul G. Richardson +28 more
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Philippe Moreau,Tamás Masszi,Norbert Grzasko,Nizar J. Bahlis,Markus Hansson,Ludek Pour,Irwindeep Sandhu,Peter Ganly,Bartrum W Baker,Sharon Jackson,Anne-Marie Stoppa,D. Simpson,Peter Gimsing,Antonio Palumbo,Laurent Garderet,Michele Cavo,Shaji Kumar,Cyrille Touzeau,Francis K. Buadi,Jacob P. Laubach,Deborah Berg,J. Lin,Alessandra Di Bacco,Ai Min Hui,Helgi van de Velde,Paul G. Richardson +25 more